Helena Kupcova Skalnikova

Dr. Helena Kupcova Skalnikova

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2013 in Biochimie
Verified
Journal Article
Closed access
HSHelena Kupcova Skalnikova
Helena Kupcova Skalnikova

9 March 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
YPYuriy Petrenko
Yuriy Petrenko
IVIrena Vackova
Irena Vackova
KKKristyna Kekulova
Kristyna Kekulova
MCMilada Chudickova
Milada Chudickova
ZKZuzana Koci
Zuzana Koci
SKSarka Kubinova
Sarka Kubinova
Multipotent mesenchymal stromal cells (MSCs) can be considered an accessible therapeutic tool for regenerative medicine. Here, we compared the growth kinetics, immunophenotypic and immunomodulatory properties, gene expression and secretome profile of MSCs derived from human adult bone marrow (BM-MSCs), adipose tissue (AT-MSCs) and Wharton’s jelly (WJ-MSCs) cultured in clinically-relevant conditions, with the focus on the neuroregenerative potential. All the cell types were positive for CD10/CD29/CD44/CD73/CD90/CD105/HLA-ABC and negative for CD14/CD45/CD235a/CD271/HLA-DR/VEGFR2 markers, but they differed in the expression of CD34/CD133/CD146/SSEA-4/MSCA-1/CD271/HLA-DR markers. BM-MSCs displayed the highest immunomodulatory activity compared to AT- and WJ-MSCs. On the other hand, BM-MSCs secreted the lower content and had the lower gene expression of neurotrophic growth factors compared to other cell lines, which may be caused by the higher sensitivity of BM-MSCs to nutrient limitations. Despite the differences in growth factor secretion, the MSC secretome derived from all cell sources had a pronounced neurotrophic potential to stimulate the neurite outgrowth of DRG-neurons and reduce the cell death of neural stem/progenitor cells after H2O2 treatment. Overall, our study provides important information for the transfer of basic MSC research towards clinical-grade manufacturing and therapeutic applications.

17 January 2011 in Proteomics
Verified
Journal Article
Closed access
PDF file
HSHelena Kupcova Skalnikova
Helena Kupcova Skalnikova
JMJan Motlik
Jan Motlik
SGSuresh Jivan Gadher
Suresh Jivan Gadher
HKHana Kovarova
Hana Kovarova

1 September 2018 in Molecular Therapy
Verified
Journal Article
Open access
MEMelvin M. Evers
Melvin M. Evers
JMJana Miniarikova
Jana Miniarikova
SJStefan Juhas
Stefan Juhas
AVAstrid Vallès
Astrid Vallès
BBBozena Bohuslavova
Bozena Bohuslavova
PKPavlina Konstantinova
Pavlina Konstantinova
Huntington's disease (HD) is a fatal neurodegenerative disorder caused by a CAG trinucleotide repeat expansion in the huntingtin gene. Previously, we showed strong huntingtin reduction and prevention of neuronal dysfunction in HD rodents using an engineered microRNA targeting human huntingtin, delivered via adeno-associated virus (AAV) serotype 5 vector with a transgene encoding an engineered miRNA against HTT mRNA (AAV5-miHTT). One of the challenges of rodents as a model of neurodegenerative diseases is their relatively small brain, making successful translation to the HD patient difficult. This is particularly relevant for gene therapy approaches, where distribution achieved upon local administration into the parenchyma is likely dependent on brain size and structure. Here, we aimed to demonstrate the translation of huntingtin-lowering gene therapy to a large-animal brain. We investigated the feasibility, efficacy, and tolerability of one-time intracranial administration of AAV5-miHTT in the transgenic HD (tgHD) minipig model. We detected widespread dose-dependent distribution of AAV5-miHTT throughout the tgHD minipig brain that correlated with the engineered microRNA expression. Both human mutant huntingtin mRNA and protein were significantly reduced in all brain regions transduced by AAV5-miHTT. The combination of widespread vector distribution and extensive huntingtin lowering observed with AAV5-miHTT supports the translation of a huntingtin-lowering gene therapy for HD from preclinical studies into the clinic.

23 December 2019 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
MBMariana Bravo-Hernandez
Mariana Bravo-Hernandez
TTTakahiro Tadokoro
Takahiro Tadokoro
MNMichael R. Navarro
Michael R. Navarro
OPOleksandr Platoshyn
Oleksandr Platoshyn
YKYoshiomi Kobayashi
Yoshiomi Kobayashi
MMMartin Marsala
Martin Marsala

Verified
Journal Article
Open access
PDF file
HSHelena Kupcova Skalnikova
Helena Kupcova Skalnikova
JCJana Cizkova
Jana Cizkova
JCJakub Cervenka
Jakub Cervenka
PVPetr Vodicka
Petr Vodicka
Melanoma is a skin cancer with permanently increasing incidence and resistance to therapies in advanced stages. Reports of spontaneous regression and tumour infiltration with T-lymphocytes makes melanoma candidate for immunotherapies. Cytokines are key factors regulating immune response and intercellular communication in tumour microenvironment. Cytokines may be used in therapy of melanoma to modulate immune response. Cytokines also possess diagnostic and prognostic potential and cytokine production may reflect effects of immunotherapies. The purpose of this review is to give an overview of recent advances in proteomic techniques for the detection and quantification of cytokines in melanoma research. Approaches covered span from mass spectrometry to immunoassays for single molecule detection (ELISA, western blot), multiplex assays (chemiluminescent, bead-based (Luminex) and planar antibody arrays), ultrasensitive techniques (Singulex, Simoa, immuno-PCR, proximity ligation/extension assay, immunomagnetic reduction assay), to analyses of single cells producing cytokines (ELISpot, flow cytometry, mass cytometry and emerging techniques for single cell secretomics). Although this review is focused mainly on cancer and particularly melanoma, the discussed techniques are in general applicable to broad research field of biology and medicine, including stem cells, development, aging, immunology and intercellular communication.